Press ReleasePierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHED15 November 2021Geneva, Switzerland, Castres, France (November 15, 2021) – The EspeRare Foundation and the Pierre Fabre group announced today the start of the EDELIFE clinical trial aimed at confirming the safety and efficacy of ER004, a prenatal treatment for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia), a rare and debilitating congenital disease. If positive, the study could lead to the first approved treatment for XLHED by 2026.
Press ReleaseRARE DISEASE DAY – February 28th, 20236 February 2023Pierre Fabre pursues its commitment against rare diseases in the pediatric, oncology and dermatology fields. The diseases are rare, but they impact a lot of people : nearly 300 million people are affected worldwide1.
We take care of life by designing and developing innovative solutions inspired by consumers and patients, and contributing to the well-being of everyone from health to beauty.